Stockscreener 앱 받기
15.63
1.36%
0.21
시간 외 거래:
15.60
-0.03
-0.19%
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq
Mineralys Therapeutics to Announce First Quarter 2025 - GlobeNewswire
Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected - Stock Titan
Trend Tracker for (MLYS) - news.stocktradersdaily.com
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM - MSN
Mineralys Therapeutics Inc [MLYS] Records 50-Day SMA of $12.99 - knoxdaily.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Renaissance Technologies LLC - Defense World
Director Makes Bold Move with Multi-Million Dollar Stock Purchase! - TipRanks
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Mineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published study - MSN
Lorundrostat shows promise in hypertension trial By Investing.com - Investing.com South Africa
Mineralys Therapeutics (MLYS) Shares Advance on Promising Hypert - GuruFocus
Lorundrostat shows promise in hypertension trial - Investing.com
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - The Manila Times
Mineralys Therapeutics Announces Publication of Pivotal - GlobeNewswire
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com India
Mineralys Therapeutics chief medical officer sells $165,185 in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com
Mineralys Therapeutics Executives Sell Shares - TradingView
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow
SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada
Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia
ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum
3 Best Stocks to Buy Now, 4/1/2025, According to Top Analysts - The Globe and Mail
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) - TradingView
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan
Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN
0.39%
3.66%
자본화:
|
볼륨(24시간):